Korcomptenz and Hindsait Partner to Transform Healthcare Operations with Responsible AI 
Sofwave™ Wins 2023 NewBeauty Award For Best Non-Invasive Cellulite Treatment
This year’s award is successive to last year’s recognition as NewBeauty’s winner for “Best in Latest Ultrasound” categorySAN CLEMENTE, Calif.,...
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by 2025 -- -- The...
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on Employee Engagement, Sustainability and Corporate...
Dyadic to Present at World Vaccine Congress Washington 2023
JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
MedAvail Postpones Reporting of Fourth Quarter and FY 2022 Financial Results
PHOENIX, March 30, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ: MDVL) (“MedAvail” or the “Company”), an innovative pharmacy technology...
Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F
Daix (France), Long Island City (New York, United States), March 30, 2023 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage...
IMUNON Reports 2022 Financial Results and Provides Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Rumi Scientific Appoints Allen A. Fienberg, Ph.D., as Chief Executive Officer and Chairman of the Board of Directors
NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Rumi Scientific (“Rumi”), a developer of therapies for rare and neurodegenerative diseases...
Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update
NORCROSS, Ga., March 30, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
Achieve Life Sciences Announces Refresh to Board of Directors
SEATTLE, Wash. and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage...
Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
– Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy...
InnovAge Diversifies Board of Directors with New Independent Director
InnovAge Diversifies Board of Directors with New Independent Director InnovAge announced the appointment of Patty Fontneau to its Board of...
PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023
Company has completed Phase 3 manufacturing of PDS0101 for randomized, controlled, registrational trial in recurrent/metastatic HPV16-positive head and neck cancerFLORHAM...
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
Expects to announce clinical trial data from multiple oncology programs in the second half of 2023Extends cash runway into second...
Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office
MENLO PARK, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an...
Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update
- 2022 was a landmark year for women in the U.S. due to the overturn of Roe v. Wade which...
Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update
Conference Call and Webcast Today at 4:30 p.m. ET 2022 Daré Key Portfolio Accomplishments: License Agreement with Organon to Commercialize...
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer
Media Release Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patientsExpansion based on...
Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis
Seattle, March 30, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies...
BioAdaptives Inc. Announced Today the Signing of a License for Eye Health due to Myopia and Presbyopia; a Patent Valued at US$ 570,000,000
LAS VEGAS, NV, March 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT) announced today the signing...